Pharma Equity Group A/S
PEG-A.CO
NASDAQ Copenhagen1.11
DKK
-0.06
- -
Pharma Equity Group A/S
PEG-A.CO
(NASDAQ Copenhagen)
Recent
price
1.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pharma Equity Group A/S Pharma Equity Group A/S is a Denmark-based investment company focused on the life sciences sector, particularly early-stage biotechnology investments aimed at developing innovative therapies for unmet medical needs in serious, acute, and chronic inflammatory diseases. The company, founded in 2002 and headquartered in Hørsholm, Denmark, operates primarily through its wholly-owned subsidiary Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical firm that advances drug candidates via repositioning of existing drugs into novel local administration formulations to minimize systemic side effects and enhance efficacy; its pipeline includes candidates such as RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 targeting conditions like peritonitis, Crohn’s disease, pouchitis, and colorectal cancer-related inflammation, with most programs in phase II clinical development. Pharma Equity Group A/S supports Reponex’s efforts by providing strategic, financial, and business development resources, leveraging its network of industry partners, advisors, and professionals to create a cost-efficient environment for rapid resource mobilization and regulatory compliance aligned with standards from authorities like the FDA and EMA. Listed on Nasdaq Copenhagen, the company targets global markets without geographic limitations as a holding entity for life science activities, seeking strategic partnerships post-phase III to commercialize products independently or collaboratively. In recent developments, Pharma Equity Group A/S, formerly known as Blue Vision and listed since November 4, 2009, launched a conditional takeover offer for Reponex Pharmaceuticals A/S on April 5, 2022, which received approval from the Danish Financial Supervisory Authority and Nasdaq Copenhagen on February 27, 2023, fully integrating Reponex into its portfolio; additionally, as of October 11, 2024, DMZ Holding ApS increased its ownership stake in Pharma Equity Group A/S from 7.57% to over 10% through share accumulation.